Cerebral amyloid angiopathy is a cerebrovascular disease directly implicated in Alzheimer’s disease pathogenesis through amyloid-β deposition. Growing evidence has shown a pivotal role of chronic neuroinflammation both in cerebral amyloid angiopathy and Alzheimer’s disease.
Objective:
The aim of this study was to investigate whether circulating levels of the complement 3, a crucial component of the innate immune system, are increased in patients with cerebral amyloid angiopathy.
Methods:
Serum complement 3 levels were retrospectively measured by a sandwich enzyme-linked immunosorbent assay in a single-center cohort of patients with mild cognitive impairment. The diagnosis of cerebral amyloid angiopathy was based on the modified Boston criteria. Logistic regression analysis was performed to identify the predictive factors for cerebral amyloid angiopathy.
Results:
We analyzed 55 mild cognitive impairment patients (mean age [standard deviation]: 76.3 [6.8] years; 33 [60% ] men). Complement 3 levels were significantly increased in cerebral amyloid angiopathy patients (n = 16) compared with those without cerebral amyloid angiopathy (n = 39) (median [interquartile range]: 0.43 [0.34–0.65] versus 0.35 [0.25–0.45], respectively; p = 0.040). Univariate and multivariate logistic regression analysis revealed that increased complement 3 levels were significantly associated with cerebral amyloid angiopathy. After selection of the best predictive model using stepwise selection, complement 3 was preserved as a significant independent predictive factor for cerebral amyloid angiopathy (odds ratio per 0.1 unit/mL increase [95% confidence interval]: 1.407 [1.042–1.899]; p = 0.026).
Conclusion:
Complement activation may play a pivotal role in cerebral amyloid angiopathy. Complement 3 may be a novel diagnostic biomarker for cerebral amyloid angiopathy.
ThalDR, GriffinWS, de VosRA, GhebremedhinE (2008) Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease. Acta Neuropathol115, 599–609.
2.
CarareRO, AldeaR, AgarwalN, BacskaiBJ, BechmanI, BocheD, BuG, BultersD, ClemensA, CountsSE, de LeonM, EidePK, FossatiS, GreenbergSM, HamelE, HawkesCA, Koronyo-HamaouiM, HainsworthAH, HoltzmanD, IharaM, JeffersonA, KalariaRN, KippsCM, KanninenKM, LeinonenV, McLaurinJ, MinersS, MalmT, NicollJAR, PiazzaF, PaulG, RichSM, SaitoS, ShihA, ScholtzovaH, SnyderH, SnyderP, ThormodssonFR, van VeluwSJ, WellerRO, WerringDJ, WilcockD, WilsonMR, ZlokovicBV, VermaA (2020) Clearance of interstitial fluid (ISF) and CSF (CLIC) group— part of Vascular Professional Interest Area (PIA). Alzheimers Dement (Amst)12, e12053.
MiaoJ, XuF, DavisJ, Otte-HollerI, VerbeekMM, Van NostrandWE (2005) Cerebral microvascular amyloid β protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid β precursor protein. Am J Pathol167, 505–515.
5.
CisternasP, TaylorX, Lasagna-ReevesCA (2019) The amyloid-tau-neuroinflammation axis in the context of cerebral amyloid angiopathy. Int J Mol Sci20, 6319.
TanskanenM, LindsbergPJ, TienariPJ, PolvikoskiT, SulkavaR, VerkkoniemiA, RastasS, PaetauA, Kiuru-EnariS (2005) Cerebral amyloid angiopathy in a 95+ cohort: Complement activation and apolipoprotein E (ApoE) genotype. Neuropathol Appl Neurobiol31, 589–599.
8.
FanR, DeFilippisK, Van NostrandWE (2007) Induction of complement proteins in a mouse model for cerebral microvascular Aβ deposition. J Neuroinflammation4, 22.
9.
ZhuX, HatfieldJ, SullivanJK, XuF, Van NostrandWE (2020) Robust neuroinflammation and perivascular pathology in rTg-DI rats, a novel model of microvascular cerebral amyloid angiopathy. J Neuroinflammation17, 78.
10.
ZabelM, SchragM, CroftonA, TungS, BeaufondP, Van OrnamJ, DininniA, VintersHV, CoppolaG, KirschWM (2013) A shift in microglial β-amyloid binding in Alzheimer’s disease is associated with cerebral amyloid angiopathy. Brain Pathol23, 390–401.
11.
YangAC, VestRT, KernF, LeeDP, AgamM, MaatCA, LosadaPM, ChenMB, SchaumN, KhouryN, TolandA, CalcuttawalaK, ShinH, PalovicsR, ShinA, WangEY, LuoJ, GateD, Schulz-SchaefferWJ, ChuP, SiegenthalerJA, McNerneyMW, KellerA, Wyss-CorayT (2022) A human brain vascular atlas reveals diverse mediators of Alzheimer’s risk. Nature603, 885–892.
12.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
13.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
14.
BergL, MillerJP, BatyJ, RubinEH, MorrisJC, FigielG (1992) Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol31, 242–249.
LiuS, SuzukiH, ItoH, KorenagaT, AkatsuH, MenoK, UchidaK (2019) Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment. Alzheimers Dement (Amst)11, 85–97.
17.
SaitoS, ShinmyozuK, KawakamiD, YamauchiM, IkedaS, HattoriY, YamamotoR, HayakawaN, IharaM (2021) Conversion from cilostazol to OPC-13015 linked to mitigation of cognitive impairment. Alzheimers Dement (N Y)7, e12182.
18.
FazekasF CJ, AlaviA, HurtigHI, ZimmermanRA (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol149, 351–356.
19.
CordonnierC, PotterGM, JacksonCA, DoubalF, KeirS, SudlowCL, WardlawJM, Al-Shahi SalmanR (2009) Improving interrater agreement about brain microbleeds: Development of the Brain Observer MicroBleed Scale (BOMBS). Stroke40, 94–99.
20.
GreenbergSM, CharidimouA (2018) Diagnosis of cerebral amyloid angiopathy: Evolution of the Boston Criteria. Stroke49, 491–497.
21.
LiuZ, TangQ, WenJ, TangY, HuangD, HuangY, XieJ, LuoY, LiangM, WuC, LuZ, TanA, GaoY, WangQ, JiangY, YaoZ, LinX, ZhangH, MoZ, YangX (2016) Elevated serum complement factors 3 and 4 are strong inflammatory markers of the metabolic syndrome development: A longitudinal cohort study. Sci Rep6, 18713.
22.
NadarSK, LipGY (2007) New insights into complement C3 and inflammation in hypertension. J Hum Hypertens21, 261–263.
23.
DelangheJR, SpeeckaertR, SpeeckaertMM (2014) Complement C3 and its polymorphism: Biological and clinical consequences. Pathology46, 1–10.
24.
JanssenBJ, HuizingaEG, RaaijmakersHC, RoosA, DahaMR, Nilsson-EkdahlK, NilssonB, GrosP (2005) Structures of complement component C3 provide insights into the function and evolution of immunity. Nature437, 505–511.
CarareRO, Bernardes-SilvaM, NewmanTA, PageAM, NicollJA, PerryVH, WellerRO (2008) Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: Significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol34, 131–144.
FoidlBM, OberacherH, MarksteinerJ, HumpelC (2020) Platelet and plasma phosphatidylcholines as biomarkers to diagnose cerebral amyloid angiopathy. Front Neurol11, 359.
29.
MarazuelaP, SoleM, Bonaterra-PastraA, PizarroJ, CamachoJ, Martinez-SaezE, KuiperijHB, VerbeekMM, de Kort AM, SchreuderF, KlijnCJM, Castillo-RibellesL, PancorboO, Rodriguez-LunaD, PujadasF, DelgadoP, Hernandez-GuillamonM (2021) MFG-E8 (LDHERIN): A novel marker associated with cerebral amyloid angiopathy. Acta Neuropathol Commun9, 154–ACTA.
30.
ChatterjeeP, TeggM, PedriniS, FaganAM, XiongC, SinghAK, TaddeiK, GardenerS, MastersCL, SchofieldPR, MulthaupG, BenzingerTLS, MorrisJC, BatemanRJ, GreenbergSM, van BuchemMA, StoopsE, VandersticheleH, TeunissenCE, HankeyGJ, WermerMJH, SohrabiHR, MartinsRN, The Dominantly Inherited Alzheimer Network (2021) Plasma amyloid-beta levels in a pre-symptomatic Dutch-type hereditary cerebral amyloid angiopathy pedigree: A cross-sectional and longitudinal investigation. Int J Mol Sci22,, 2931.
